新型 18F 标记的生长抑素受体 (SSTR) 导向的放射性示踪剂 [18F]SiTATE 在各种表达 SSTR 的肿瘤类型的成像中显示出有希望的结果。尽管甲状腺癌 (TC) 表达 SSTR，但缺乏 TC 中 [18F]SiTATE PET/CT 成像的数据。本研究探讨了 [18F]SiTATE PET/CT 在组织学证实的 TC 患者队列中的使用。作为在单个三级癌症中心进行的前瞻性观察研究的一部分，21 名 TC 患者（10 名髓质 (MTC) 和 11 名分化型 (MTC) 患者） DTC)) 接受了至少一次 [18F]SiTATE PET/CT 扫描（总共 37 次扫描）。确定肿瘤病变的平均 SUVmax 和 SUVmean、平均总肿瘤体积 (TTV) 以及 PET 上的全身 (WB)-SUVmax 和 WB-SUVmean 及其标准差 (SD)。 PET 参数与临床参数相关，包括肿瘤标志物水平（DTC 的甲状腺球蛋白、MTC 的降钙素）。分析中纳入了 89 个病变。转移灶位于骨、淋巴结、肺、软组织和甲状腺床。骨性（31 个病灶；SUVmax 8.6±±8.0；SUVmean 5.8±±5.4）和淋巴结（37 个病灶；SUVmax 8.7±±7.8；SUVmean 5.7±±5.4）转移显示出最高的摄取量。 PET 上的 MTC 疾病负担与降钙素肿瘤标志物水平显着相关（例如，TTV：r = 0.771，r2 = 0.594，p = 0.002）。对于 DTC，不存在这种相关性。我们的数据证明 [18F]SiTATE PET/CT 在一小群 MTC 和 DTC 患者中具有高度可行性。使用 [18F]SiTATE 可以克服基于 68Ga 的示踪剂的后勤缺点，并促进甲状腺癌的 SSTR 靶向 PET/CT 成像。© 2024。作者。

The novel 18F-labeled somatostatin receptor (SSTR)-directed radiotracer [18F]SiTATE demonstrated promising results for the imaging of various SSTR-expressing tumor types. Although thyroid carcinomas (TC) express SSTR, data on [18F]SiTATE PET/CT imaging in TC are lacking. This study explores the use of [18F]SiTATE PET/CT in a patient cohort with histologically proven TC.As part of a prospective observational study at a single tertiary cancer center, 21 patients with TC (10 medullary (MTC) and 11 differentiated (DTC)) who underwent at least one [18F]SiTATE PET/CT were included (37 scans in total). Mean SUVmax and SUVmean of tumoral lesions, mean total-tumor-volume (TTV), and whole-body (WB)-SUVmax and WB-SUVmean on PET with their standard deviations (SDs) were determined. PET parameters were correlated to clinical parameters including tumor marker levels (thyroglobulin for DTC, calcitonin for MTC).89 lesions were included in the analysis. Metastases were localized in the bone, lymph nodes, lung, soft tissue, and thyroid bed. Osseous (31 lesions; SUVmax 8.6 ± 8.0; SUVmean 5.8 ± 5.4) and nodal (37 lesions; SUVmax 8.7 ± 7.8; SUVmean 5.7 ± 5.4) metastases showed the highest uptake. The MTC disease burden on PET significantly correlated with the calcitonin tumor marker level (e.g., TTV: r = 0.771, r2 = 0.594, p = 0.002). For DTC, no such correlation was present.Our data demonstrate high feasibility of [18F]SiTATE PET/CT in a small cohort of patients with MTC and DTC. The use of [18F]SiTATE may overcome logistical disadvantages of 68Ga-based tracers and facilitate SSTR-targeted PET/CT imaging of thyroid carcinoma.© 2024. The Author(s).